Applications for phase 3 of the Pathway Transformation Fund (PTF) will open from Monday 4 January. The fund supports NHS organisations increase adoption of the 2020/21 Rapid Uptake Products RUPs, which are:

• Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors
• Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
• Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab

The PTF can help providers overcome practical obstacles to introducing these products, such as:

• Support set-up costs such as training and accreditation of staff;
• Pathway redesign and/or business support expertise;
• Providing funding for specialist nurses and clinical staff needed to implement a new part of the procedure; and
• Covering double running costs
• Capital costs.

NHS organisations will be able to submit applications for PTF from 4 January 2021 until 12noon, 30 April 2021. Applications should be developed and submitted with the support of HIWM RUP lead, Tammy Holmes.